Dr. Maron and Dr. Gibson Discuss Ninerafaxstat and IMPROVE-HCM
Journal of the American College of Cardiology
Ninerafaxstat to Provide Optimal Ventricular Energetics in HCM: IMPROVE-HCM
IMPROVE DiCE: A Phase 2a Trial Investigating Ninerafaxstat - A Novel Cardiac Mitotrope for the treatment of Diabetic Cardiomyopathy
IMB-10189721, a novel first-in-class partial fatty acid oxidation (pFOX) inhibitor improves cardiac remodelling and function post-myocardial infarction.
Phase 1 safety and tolerability study of IMB-1018972, a novel oral modulator of substrate utilization designed to improve cardiac metabolic efficiency and bioenergetics
You Are About to Leave Imbria Pharmaceuticals
The appearance of external hyperlinks does not constitute endorsement by Imbria Pharmaceuticals of the linked websites, or the information, products or services contained therein.
